Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744497 | 0.94 | CHRM5 (0.56) | CHRM5CHRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL23744439 | 0.94 | CHRM5 (0.56) | CHRM5CHRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL26430530 | 0.89 | CHRM5 (0.53) | CHRM5CHRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL26430556 | 0.89 | CHRM5 (0.53) | CHRM5CHRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL26086956 | 0.87 | CHRM5 (0.44) | CHRM5CHRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL23744148 | 0.86 | SIGMAR1 (0.52) | CHRM5CHRM1CHRM3CHRM2PRKAA2 | |
| SCHEMBL26430595 | 0.86 | SIGMAR1 (0.52) | CHRM5CHRM1CHRM3CHRM2PRKAA2 | |
| SCHEMBL23744502 | 0.84 | CHRM4 (0.59) | CHRM5CHRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL23744110 | 0.84 | CHRM4 (0.59) | CHRM5CHRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL23744511 | 0.84 | CHRM5 (0.49) | CHRM5CHRM1CHRM3CHRM4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM5 3/4885CHRM1 5/4885CHRM3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.